terfenadine has been researched along with verapamil in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.29) | 18.2507 |
| 2000's | 33 (47.14) | 29.6817 |
| 2010's | 31 (44.29) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HX; Gesmonde, JF; Hait, WN; Murren, JR; Reiss, M; Yang, JM | 1 |
| Achterrath, U; Duflos, M; Emig, P; Fouchard, F; Günther, E; Kutscher, B; Le Baut, G; Menciu, C; Nickel, B; Schmidt, J; Szelenyi, I | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
| Keserü, GM | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bondebjerg, J; Fuglsang, H; Naerum, L; Pedersen, J; Valeur, KR | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chavatte, P; Dubois, J; Farce, A; Furman, C; Gilleron, P; Hénichart, JP; Le Broc-Ryckewaert, D; Lemoine, A; Millet, R; Pommery, N; Wlodarczyk, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Basilico, N; Bernetti, M; Bonache de Marcos, MC; Brogi, S; Brun, R; Butini, S; Caccia, S; Camodeca, C; Campiani, G; Gemma, S; Gorelli, B; Guiso, G; Joshi, BP; Lamponi, S; Martin, RE; Moretti, V; Novellino, E; Parapini, S; Rottmann, M; Sanna Coccone, S; Saponara, S; Savini, L; Summers, RL; Taramelli, D | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Caflisch, A; Dong, J; Kolb, P; Lafleur, K; Liebl, J; Nevado, C; Unzue, A; Zahler, S; Zhao, H; Zhou, T | 1 |
| Almeida, R; Cawthorne, MA; Christiansen, E; Due-Hansen, ME; Ejsing, CS; Hansen, SV; Hudson, BD; Kassack, MU; Milligan, G; Shimpukade, B; Stocker, CJ; Ulven, T; Urban, C; Wargent, ET | 1 |
| Alam, MA; Drewes, LR; Gurrapu, S; Jonnalagadda, SK; Lueth, EA; Mereddy, VR; Nelson, GL; Ronayne, CT; Solano, LN | 1 |
| Abouf, M; Abutaleb, NS; Chen, L; Elsebaei, MM; Ghiaty, A; Hegazy, YA; Malwal, SR; Mayhoub, AS; Mohammad, H; Oldfield, E; Seleem, MN; Zhang, J | 1 |
| Chreifi, G; Cinelli, MA; Li, H; Poulos, TL; Reidl, CT; Silverman, RB | 1 |
| Abutaleb, NS; Alhashimi, M; Kassab, AE; Mayhoub, AS; Mohamed, KO; Seleem, MN; Shahin, IG; Taher, AT | 1 |
| Artursson, P; Hidalgo, IJ; Raeissi, SD; Segura-Aguilar, J | 1 |
| Dagenais, C; Ducharme, J; Pollack, GM | 1 |
| Avery, MJ; DePasquale, MJ; Fossa, AA; Leishman, DJ; Raunig, DL | 1 |
| Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N; Tannergren, C | 1 |
| Avery, M; Fermini, B; Fossa, AA; Raunig, DL; Wang, E; Wisialowski, T; Wolfgang, E | 1 |
| Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Antzelevitch, C; Fish, JM | 1 |
| Brunelle, F; Castro-Perez, J; Delatour, C; Hoes, I; Labrique, X; Leclercq, L | 1 |
| Hoffer, M; Werle, M | 1 |
| Fukuda, H; Kamikozawa, Y; Ohashi, R; Sugiura, M; Tamai, I; Yabuuchi, H | 1 |
| Gorski, JC; Hall, SD; Hamman, MA; Lemma, GL; Wang, Z; Zaheer, NA | 1 |
| Antzelevitch, C; Fish, JM; Ho, WK; Kim, YS; Lee, SH; Welchons, DR | 1 |
| Bergman, E; Bondesson, U; Forsell, P; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N | 1 |
| Nemes, P; Vertes, A | 1 |
| Hokama, N; Miura, M; Sakugawa, T; Suzuki, T; Tateishi, T; Uno, T | 1 |
| Miura, M; Uno, T | 1 |
| Ai, H; Gu, Y; Hao, G; Li, Y; Peng, Y; Sun, J; Wang, G; Wu, X; Zhang, J; Zhang, X; Zheng, Y; Zhou, F | 1 |
| Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K | 1 |
| Ohkawa, T; Tanaka, Y; Yasui, H | 1 |
| Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Fujii, M; Imaizumi, Y; Ohya, S; Yamamura, H | 1 |
| Covell, DG | 1 |
| Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ | 1 |
| Bondesson, U; Hedeland, M; Lennernäs, H; Sjögren, E | 1 |
| Bedada, SK; Neerati, P; Yellu, NR | 1 |
| Árpádffy-Lovas, T; Gazdag, P; Geramipour, A; Jost, N; Kohajda, Z; Orvos, P; Szlovák, J; Tálosi, L; Tóth, D; Varró, A; Virág, L | 1 |
| Hinoi, E; Miyawaki, I; Tsubouchi, T; Watanabe, K; Yamada, T | 1 |
| Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
2 review(s) available for terfenadine and verapamil
| Article | Year |
|---|---|
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
Topics: Animals; Computer Simulation; Drug Design; Humans; Isoquinolines; Neoplasms; Protein Kinase Inhibitors; Quinoxalines; Receptor, EphB2; Structure-Activity Relationship; Xanthine | 2016 |
Clinical pharmacokinetics of fexofenadine enantiomers.
Topics: Antifungal Agents; Calcium Channel Blockers; Drug Interactions; Histamine H1 Antagonists; Humans; Itraconazole; Stereoisomerism; Terfenadine; Verapamil | 2010 |
4 trial(s) available for terfenadine and verapamil
| Article | Year |
|---|---|
Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Topics: Adult; Algorithms; Anti-Allergic Agents; Area Under Curve; Biological Availability; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Female; Humans; In Vitro Techniques; Intestinal Absorption; Intestines; Jejunum; Male; Membrane Transport Modulators; Membrane Transport Proteins; Regional Blood Flow; Spectrophotometry, Ultraviolet; Terfenadine; Verapamil | 2003 |
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Topics: Adult; Area Under Curve; Biological Availability; Calcium Channel Blockers; Cimetidine; Drug Interactions; Half-Life; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Male; Probenecid; Terfenadine; Uricosuric Agents; Verapamil | 2005 |
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Half-Life; Histamine H1 Antagonists; Humans; Male; Stereoisomerism; Terfenadine; Tissue Distribution; Verapamil | 2006 |
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Terfenadine; Verapamil; Young Adult | 2009 |
64 other study(ies) available for terfenadine and verapamil
| Article | Year |
|---|---|
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.
Topics: Affinity Labels; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Division; Dihydropyridines; Doxorubicin; Drug Resistance; Flupenthixol; Humans; Membrane Glycoproteins; Mice; Rhodamine 123; Rhodamines; Structure-Activity Relationship; Terfenadine; Tumor Cells, Cultured | 1993 |
New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
Topics: Acetylcholine; Animals; Anti-Allergic Agents; Bronchoalveolar Lavage; Capillary Permeability; Carbachol; Eosinophilia; Guinea Pigs; Histamine Release; Hypersensitivity; In Vitro Techniques; Indoleacetic Acids; Interleukin-4; Interleukin-5; Male; Mast Cells; Muscle Contraction; Muscle, Smooth; Peritoneal Cavity; Polyunsaturated Alkamides; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rhinitis, Allergic, Perennial; Structure-Activity Relationship; Trachea | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship | 2005 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
Topics: Cathepsin C; Dipeptides; Enzyme Inhibitors; Humans; Molecular Structure; Nitriles; Stereoisomerism; Structure-Activity Relationship | 2006 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
Topics: Androgen Antagonists; Azepines; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Humans; Hydrophobic and Hydrophilic Interactions; Male; Models, Molecular; Prostatic Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
Topics: Aminoquinolines; Animals; Antimalarials; Biological Transport; Cell Line; Chloroquine; Clotrimazole; Drug Resistance; Female; Half-Life; Hemeproteins; Humans; Malaria; Male; Membrane Transport Proteins; Mice; Models, Molecular; Mutation; Oocytes; Piperazines; Plasmodium berghei; Plasmodium falciparum; Protozoan Proteins; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Ventricular Pressure; Xenopus laevis | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Discovery; Glucose Tolerance Test; Hypoglycemic Agents; Ligands; Lipids; Mice; Mice, Inbred C57BL; Models, Molecular; Phenylpropionates; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2016 |
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Coumarins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Monocarboxylic Acid Transporters; Structure-Activity Relationship; Symporters | 2016 |
Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Alkynes; Animals; Anti-Bacterial Agents; Half-Life; Methicillin-Resistant Staphylococcus aureus; Mice; Microsomes, Liver; Staphylococcal Infections; Thiazoles | 2018 |
First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate.
Topics: Aminoquinolines; Animals; Aspartic Acid; Blood-Brain Barrier; Catalytic Domain; Crystallography, X-Ray; Enzyme Assays; Enzyme Inhibitors; Humans; Isoenzymes; Microsomes, Liver; Molecular Structure; Mutagenesis, Site-Directed; Mutation; Nitric Oxide Synthase Type I; Permeability; Protein Binding; Rats; Structure-Activity Relationship | 2020 |
Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Thiazoles | 2020 |
Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Topics: Anti-Anxiety Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Catalytic Domain; Cell Polarity; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Enzyme Inhibitors; Epithelial Cells; Gene Expression; Histamine H1 Antagonists; Humans; Hydroxylation; Intestinal Mucosa; Intestines; Ketoconazole; Kinetics; Oligonucleotide Probes; Oxidoreductases, N-Demethylating; Piperidines; RNA, Messenger; Terfenadine; Tritium; Verapamil | 1999 |
Uptake and efflux of the peptidic delta-opioid receptor agonist.
Topics: Analgesics, Opioid; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Calcium Channel Blockers; Carrier Proteins; Digoxin; Enkephalin, D-Penicillamine (2,5)-; Enzyme Inhibitors; Estradiol; Histamine H1 Antagonists; Male; Mice; Mice, Knockout; Perfusion; Receptors, Opioid, delta; Terfenadine; Verapamil | 2001 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart Rate; Long QT Syndrome; Male; Piperidines; Pyridines; Terfenadine; Verapamil | 2002 |
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Chromatography, High Pressure Liquid; Depression, Chemical; Drug Interactions; Drug Stability; Fluorometry; Histamine H1 Antagonists; Humans; In Vitro Techniques; Kinetics; Rhodamines; Ritonavir; Terfenadine; Time Factors; Verapamil | 2002 |
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Topics: Animals; Antipsychotic Agents; Bepridil; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Cisapride; Delayed Rectifier Potassium Channels; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Guinea Pigs; Heart Rate; Histamine H1 Antagonists; Humans; In Vitro Techniques; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Piperidines; Potassium Channels, Voltage-Gated; Pyridines; Risperidone; Terfenadine; Verapamil | 2004 |
Role of sodium and calcium channel block in unmasking the Brugada syndrome.
Topics: Ajmaline; Animals; Bundle-Branch Block; Calcium Channel Blockers; Dogs; Electrocardiography; Flecainide; Procainamide; Sodium Channel Blockers; Terfenadine; Verapamil | 2004 |
Use of a five-channel multiplexed electrospray quadrupole time-of-flight hybrid mass spectrometer for metabolite identification.
Topics: Animals; Bile; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Humans; Ketotifen; Microsomes, Liver; Pharmaceutical Preparations; Rats; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Terfenadine; Verapamil | 2005 |
Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Chitosan; Dose-Response Relationship, Drug; Electric Impedance; Glutathione; Guinea Pigs; Ileum; In Vitro Techniques; Reproducibility of Results; Rhodamine 123; Sulfhydryl Compounds; Terfenadine; Verapamil | 2006 |
Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Topics: Adenosine Triphosphatases; Animals; Anti-Allergic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Biological Transport, Active; Brain; Chromatography, Liquid; Intestinal Absorption; Kinetics; LLC-PK1 Cells; Male; Mass Spectrometry; Mice; Mice, Knockout; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Stimulation, Chemical; Swine; Terfenadine; Verapamil | 2006 |
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome.
Topics: Animals; Arrhythmias, Cardiac; Biological Transport; Calcium Channel Blockers; Dogs; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrocardiography; Female; In Vitro Techniques; Male; NAV1.5 Voltage-Gated Sodium Channel; Pinacidil; Plant Extracts; Plant Roots; Potassium Channels; Salvia miltiorrhiza; Sodium; Sodium Channel Agonists; Sodium Channel Blockers; Sodium Channels; Stimulation, Chemical; Terfenadine; Verapamil | 2006 |
First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model.
Topics: Animals; Antipyrine; Bile; Calcium Channel Blockers; Dose-Response Relationship, Drug; Histamine H1 Antagonists; Intestinal Absorption; Liver; Models, Animal; Perfusion; Swine; Terfenadine; Verapamil | 2006 |
Laser ablation electrospray ionization for atmospheric pressure, in vivo, and imaging mass spectrometry.
Topics: Atmospheric Pressure; Humans; Molecular Weight; Particle Size; Plant Leaves; Plant Roots; Plant Stems; Proteins; Reserpine; Seedlings; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Tagetes; Terfenadine; Verapamil | 2007 |
20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Digoxin; Etoposide; Ginsenosides; Herb-Drug Interactions; Humans; Ileum; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Terfenadine; Verapamil | 2010 |
The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Topics: Administration, Oral; Animals; Anti-Allergic Agents; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Biological Availability; Colon; Delayed-Action Preparations; Diclofenac; Diltiazem; Dogs; Dose-Response Relationship, Drug; Hypoglycemic Agents; Metformin; Muscarinic Agonists; Quinuclidines; Terfenadine; Thiophenes; Verapamil | 2010 |
Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Imipramine; Male; Ondansetron; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Risperidone; Tandem Mass Spectrometry; Terfenadine; Validation Studies as Topic; Verapamil | 2011 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Topics: Action Potentials; Biological Assay; Cell Line; Cisapride; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; HEK293 Cells; High-Throughput Screening Assays; Humans; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyridines; Pyrimidinones; Sodium Channels; Terfenadine; Transfection; Verapamil | 2012 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Colchicine; Computational Biology; Cyclin-Dependent Kinases; Dasatinib; Databases, Genetic; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Pimozide; Purines; Pyrimidines; Terfenadine; Thiazoles; Tubulin Modulators; Verapamil | 2012 |
Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cardiotoxins; Clomipramine; Cyclophosphamide; Disease Models, Animal; Edema; Gentamicins; Heart Diseases; Heart Rate; Heart Ventricles; Larva; Microinjections; Nimodipine; Pericardium; Quinidine; Terfenadine; Tetracycline; Toxicity Tests; Verapamil; Yolk Sac; Zebrafish | 2014 |
Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
Topics: Animals; Bile; Biological Transport; Biotransformation; Chromatography, Liquid; Drug Interactions; Hepatobiliary Elimination; Infusions, Intravenous; Kidney; Liver; Male; Models, Biological; Swine; Tandem Mass Spectrometry; Terfenadine; Verapamil | 2014 |
Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Drug Interactions; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Permeability; Rats; Rats, Wistar; Resveratrol; Stilbenes; Terfenadine; Verapamil | 2016 |
Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Female; Heart Ventricles; Humans; Ion Channels; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Rabbits; Sotalol; Sulfonamides; Terfenadine; Tissue Donors; Verapamil | 2019 |
Telemetered common marmosets is useful for the assessment of electrocardiogram parameters changes induced by multiple cardiac ion channel inhibitors.
Topics: Animals; Astemizole; Body Temperature; Calcium Channel Blockers; Callithrix; Electrocardiography; Flecainide; Male; Models, Animal; Quinidine; Risk Assessment; Sotalol; Telemetry; Terfenadine; Verapamil; Voltage-Gated Sodium Channel Blockers | 2019 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |